Nursing care
Alkylating agents: myelosuppression, bladder protection and safe handling
Written and reviewed by Sophia Chen, MSN, RN, OCN · 4 min read · Updated October 2026
Short answer
Alkylating agents such as cyclophosphamide and ifosfamide damage DNA so dividing cells cannot replicate. Nursing priorities are infection precautions during myelosuppression, preventing haemorrhagic cystitis with hydration, frequent voiding and mesna as ordered, watching for ifosfamide encephalopathy and kidney injury, counselling about infertility and fetal harm, and handling the drug as hazardous.
How alkylating agents damage cancer cells
Alkylating agents attach chemical groups to DNA and link its strands together, so the cell cannot copy its genetic material and dies. Because this damage can happen at any point in the cell cycle, these drugs are described as cell-cycle nonspecific, and they affect healthy fast-dividing tissue such as bone marrow, hair follicles and the gut lining.
Cyclophosphamide is given intravenously or orally for many cancers and some autoimmune diseases, while ifosfamide is an intravenous drug used mainly for certain solid tumours. Both are activated by the body, and their breakdown products can irritate the bladder lining, which is why urinary care runs through every nursing plan for these drugs.
Myelosuppression and infection risk
Both labels warn of myelosuppression, including neutropenia, thrombocytopenia and anaemia, with serious and sometimes fatal infections. Latent infections can also reactivate. Review the complete blood count before each cycle as ordered, and report a falling neutrophil or platelet count before the next dose is prepared rather than after.
Teach the patient to check their temperature and report fever, chills, sore throat, a new cough or burning on urination promptly, because fever during neutropenia is an emergency. Bleeding precautions apply when platelets are low. Hair loss, nausea and vomiting are common and need anticipatory teaching and antiemetics as prescribed.
Protecting the bladder and kidneys
Haemorrhagic cystitis, with blood in the urine, can be severe and occasionally fatal. Hydration with frequent bladder emptying reduces the risk, and mesna is given with ifosfamide, and sometimes with cyclophosphamide, to protect the bladder. Encourage fluids as ordered, ask the patient to void often, including overnight, and report pink or red urine, pain or urgency.
The ifosfamide label calls for a urinalysis before each dose and advises withholding the drug if haematuria is present until it resolves, so check that result is available. Ifosfamide also carries boxed warnings for nephrotoxicity and encephalopathy. Report confusion, drowsiness, hallucinations, blurred vision or seizures immediately, and track intake, output and kidney function.
Heart, lungs, fertility and hazardous-drug handling
Cyclophosphamide can cause myocarditis, pericardial effusion, arrhythmias and heart failure, and pulmonary toxicity such as pneumonitis and fibrosis. Report new breathlessness, chest pain, cough or oedema. The drug can cause infertility in both sexes, which may be permanent, so fertility preservation questions belong before treatment starts.
Both drugs can harm a fetus, and patients of reproductive potential are advised to use effective contraception. These are hazardous drugs: wear chemotherapy-rated gloves and follow local handling and disposal procedures. Teach patients taking oral cyclophosphamide at home to avoid handling capsules with bare skin and to drink plenty of fluids.
Worked example: a patient with pink urine
Consider a hypothetical patient on day two of cyclophosphamide who says their urine looks pink and that they plan to drink less so they will not have to get up at night. Possible responses include reassuring the patient that colour changes are expected, agreeing that restricting fluids will help them sleep, notifying the prescriber while encouraging fluids and frequent voiding, or giving a PRN analgesic and rechecking tomorrow.
Notifying the prescriber and continuing hydration and voiding is the best choice, because pink urine may signal haemorrhagic cystitis, and concentrated urine left in the bladder increases contact with irritating metabolites. Reassurance delays treatment, fluid restriction makes the problem worse, and pain relief alone hides a finding that changes the plan.
Sources and further reading
DailyMed: Cyclophosphamide for injection prescribing information. Myelosuppression, haemorrhagic cystitis with hydration, frequent voiding and mesna, cardiac and pulmonary toxicity, infertility, embryo-fetal toxicity and hazardous handling.
DailyMed: Ifosfamide for injection prescribing information. Boxed warning for myelosuppression, encephalopathy, nephrotoxicity and urotoxicity, mesna use and urinalysis before each dose.
MedlinePlus: Cyclophosphamide. Patient teaching on fluids, frequent urination, reporting pink urine and wearing gloves to handle capsules.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
What is mesna and why is it given with ifosfamide?
Mesna is a bladder protectant given with ifosfamide to reduce the incidence and severity of haemorrhagic cystitis. It does not replace hydration and frequent voiding, which remain part of the plan.
What should a patient on cyclophosphamide report right away?
Fever or other signs of infection, pink or red urine or painful urination, unusual bleeding or bruising, new shortness of breath or chest pain, and swelling.
Why is a urinalysis checked before each ifosfamide dose?
Ifosfamide can damage the bladder and kidneys. The label advises a urinalysis before each dose and withholding the drug if haematuria is present until it resolves.
More on pharmacology
Guides on this